CG Oncology (CGON) Equity Average (2023 - 2026)

CG Oncology has reported Equity Average for 4 years, with the latest figure at $922.2 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 28.25% year-over-year to $922.2 million; the trailing twelve-month figure through Mar 2026 stood at $922.2 million (up 28.25% YoY), and the FY2025 full-year result was $743.0 million, up 143.49% from the prior year.
• Equity Average for Q1 2026 stood at $922.2 million, up from $720.1 million in the prior quarter.
• The five-year high for Equity Average was $922.2 million in Q1 2026, with the low at -$115.3 million in Q4 2023.
• Historically, Equity Average has averaged $448.5 million across 4 years, with a median of $597.9 million in 2024.
• Annual changes were most pronounced in 2024 — Equity Average soared 711.04% — and 2025, when it climbed 13.39%.
• CG Oncology's Equity Average stood at -$115.3 million in 2023, then jumped by 650.6% to $635.1 million in 2024, then rose by 13.39% to $720.1 million in 2025, then increased by 28.06% to $922.2 million in 2026.
• The last three Equity Average figures came in at $922.2 million (Q1 2026), $720.1 million (Q4 2025), and $679.0 million (Q3 2025), per Business Quant data.